New immune therapy trial targets Virus-Linked head and neck cancer
NCT ID NCT07172256
Summary
This study is testing a new immune-boosting drug called CUE-101, both alone and combined with the immunotherapy drug pembrolizumab, for people newly diagnosed with advanced head and neck cancer caused by HPV-16. The goal is to see if these treatments given before standard care are safe and can help shrink tumors by activating the body's immune system against the cancer. About 30 people with specific genetic markers will participate.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yale University
New Haven, Connecticut, 06510, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.